Drug partnerships and global practices

Area of Science:

• Global Health
• Pharmaceutical Research
• Infectious Diseases

Background:

• Tuberculosis (TB) is a major threat to individuals with HIV, particularly in low-income regions.
• The rise of multi-drug resistant tuberculosis (MDR-TB) exacerbates this global health crisis.
• Lack of pharmaceutical market incentives has led to a four-decade stagnation in new TB drug development.

Purpose of the Study:

• To examine the formation and function of new partnerships for drug development (PDPs).
• To address the critical shortage of treatments for 'neglected' diseases like TB.
• To explore alternative pathways for producing new drugs and vaccines.

Main Methods:

• Analysis of existing literature on pharmaceutical-state practices and PDPs.
• Case study examination of selected PDPs focused on neglected diseases.
• Tracing the development and challenges within these new collaborative models.

Main Results:

• PDPs are emerging as a response to global criticism of traditional pharmaceutical research models.
• These partnerships aim to stimulate R&D for diseases that lack commercial viability.
• Challenges exist in forging effective and sustainable alternative pathways for drug and vaccine production.

Conclusions:

• Partnerships for drug development offer a novel approach to tackling neglected diseases.
• Addressing market failures is crucial for advancing treatments for TB and similar conditions.
• Continued examination of PDP dynamics is necessary to optimize their impact on global health equity.